Pulike Biological Engineering, Inc. (SHA:603566)
China · Delayed Price · Currency is CNY 10.45
-0.10 (-0.95%)
Sep 2, 2026, 2:19 PM CST
SHA:603566 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,009 | 1,077 | 1,034 | 1,243 | 1,217 | 1,088 |
Other Revenue | 12.93 | 12.93 | 8.69 | 10.11 | 13.06 | 11.03 |
| 1,022 | 1,090 | 1,043 | 1,253 | 1,230 | 1,099 | |
Revenue Growth | -8.68% | 4.54% | -16.77% | 1.84% | 11.97% | 18.32% |
Cost of Revenue | 429.6 | 437.35 | 405.63 | 488.4 | 459.74 | 379.95 |
Gross Profit | 592.11 | 652.53 | 636.93 | 764.3 | 770.33 | 718.62 |
Selling, General & Admin | 346.85 | 361.59 | 413.65 | 450.03 | 473.74 | 391.87 |
Research & Development | 107.42 | 99.65 | 106.05 | 101.1 | 92.62 | 85.57 |
Other Operating Expenses | 11.23 | 16.1 | 15.31 | 14.62 | 12.77 | 11.29 |
Operating Expenses | 461.95 | 473.79 | 529.74 | 593.41 | 594.47 | 496.51 |
Operating Income | 130.16 | 178.73 | 107.19 | 170.89 | 175.86 | 222.11 |
Interest Expense | -0.06 | -0.06 | -0.08 | -0.92 | -0.86 | - |
Interest & Investment Income | 11.65 | 4.96 | 4.8 | 21.79 | 10.09 | 2.5 |
Currency Exchange Gain (Loss) | -0.32 | -0.32 | 0.19 | 0.22 | 0.58 | -0.22 |
Other Non Operating Income (Expenses) | -19.5 | -0.4 | -0.78 | -0.73 | -0.65 | -0.56 |
EBT Excluding Unusual Items | 121.94 | 182.92 | 111.32 | 191.25 | 185.02 | 223.84 |
Gain (Loss) on Sale of Investments | 13.8 | 10.03 | -9.97 | -17.69 | -25.57 | 20.39 |
Gain (Loss) on Sale of Assets | -1.46 | -2.09 | -12.27 | -0.6 | -0.54 | -3.34 |
Asset Writedown | -1.63 | -0.8 | -1 | -0.03 | - | - |
Other Unusual Items | 17.29 | 17.29 | 10.7 | 21.68 | 18.81 | 43.28 |
Pretax Income | 149.94 | 207.34 | 98.76 | 194.61 | 177.72 | 284.18 |
Income Tax Expense | 17.26 | 22.34 | 5.96 | 20.1 | 9.9 | 40.04 |
Net Income | 146.14 | 184.99 | 92.81 | 174.52 | 167.82 | 244.14 |
Net Income to Common | 146.14 | 184.99 | 92.81 | 174.52 | 167.82 | 244.14 |
Net Income Growth | 8.21% | 99.33% | -46.82% | 3.99% | -31.26% | 7.20% |
Shares Outstanding (Basic) | 340 | 343 | 344 | 349 | 323 | 313 |
Shares Outstanding (Diluted) | 340 | 343 | 344 | 349 | 323 | 313 |
Shares Change | 0.38% | -0.33% | -1.52% | 8.15% | 3.11% | -1.05% |
EPS (Basic) | 0.43 | 0.54 | 0.27 | 0.50 | 0.52 | 0.78 |
EPS (Diluted) | 0.43 | 0.54 | 0.27 | 0.50 | 0.52 | 0.78 |
EPS Growth | 7.80% | 100.00% | -46.00% | -3.85% | -33.33% | 8.33% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 175.75 | 281.3 | 147.73 | -22.2 | -128.8 | -105.01 |
Free Cash Flow Per Share | 0.52 | 0.82 | 0.43 | -0.06 | -0.40 | -0.34 |
Dividend Per Share | 0.600 | 0.600 | 0.400 | 0.700 | 0.350 | 0.200 |
Dividend Growth | 50.00% | 50.00% | -42.86% | 100.00% | 75.00% | -60.00% |
Gross Margin | 57.95% | 59.87% | 61.09% | 61.01% | 62.63% | 65.41% |
Operating Margin | 12.74% | 16.40% | 10.28% | 13.64% | 14.30% | 20.22% |
Profit Margin | 14.30% | 16.97% | 8.90% | 13.93% | 13.64% | 22.22% |
Free Cash Flow Margin | 17.20% | 25.81% | 14.17% | -1.77% | -10.47% | -9.56% |
EBITDA | 265.95 | 298.84 | 227.99 | 262.7 | 249.8 | 281.42 |
EBITDA Margin | 26.03% | 27.42% | 21.87% | 20.97% | 20.31% | 25.62% |
D&A For EBITDA | 135.79 | 120.11 | 120.79 | 91.81 | 73.93 | 59.31 |
EBIT | 130.16 | 178.73 | 107.19 | 170.89 | 175.86 | 222.11 |
EBIT Margin | 12.74% | 16.40% | 10.28% | 13.64% | 14.30% | 20.22% |
Effective Tax Rate | 11.51% | 10.78% | 6.03% | 10.33% | 5.57% | 14.09% |
Revenue as Reported | 1,090 | 1,090 | 1,043 | 1,253 | 1,230 | 1,099 |
Advertising Expenses | - | 27.42 | 10.27 | 5.54 | 7.62 | 7.54 |